|
|
|
|
LEADER |
04608nam a2200853Ia 4500 |
001 |
10.1186-s12916-022-02448-4 |
008 |
220718s2022 CNT 000 0 und d |
020 |
|
|
|a 17417015 (ISSN)
|
245 |
1 |
0 |
|a Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID)
|
260 |
|
0 |
|b NLM (Medline)
|c 2022
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1186/s12916-022-02448-4
|
520 |
3 |
|
|a BACKGROUND: Previous studies assessing the prevalence of COVID-19 sequelae in adults and children were performed in the absence of an agreed definition. We investigated prevalence of post-COVID-19 condition (PCC) (WHO definition), at 6- and 12-months follow-up, amongst previously hospitalised adults and children and assessed risk factors. METHODS: Prospective cohort study of children and adults with confirmed COVID-19 in Moscow, hospitalised between April and August, 2020. Two follow-up telephone interviews, using the International Severe Acute Respiratory and Emerging Infection Consortium survey, were performed at 6 and 12 months after discharge. RESULTS: One thousand thirteen of 2509 (40%) of adults and 360 of 849 (42%) of children discharged participated in both the 6- and 12-month follow-ups. PCC prevalence was 50% (95% CI 47-53) in adults and 20% (95% CI 16-24) in children at 6 months, with decline to 34% (95% CI 31-37) and 11% (95% CI 8-14), respectively, at 12 months. In adults, female sex was associated with PCC at 6- and 12-month follow-up (OR 2.04, 95% CI 1.57 to 2.65) and (OR 2.04, 1.54 to 2.69), respectively. Pre-existing hypertension (OR 1.42, 1.04 to 1.94) was associated with post-COVID-19 condition at 12 months. In children, neurological comorbidities were associated with PCC both at 6 months (OR 4.38, 1.36 to 15.67) and 12 months (OR 8.96, 2.55 to 34.82) while allergic respiratory diseases were associated at 12 months (OR 2.66, 1.04 to 6.47). CONCLUSIONS: Although prevalence of PCC declined one year after discharge, one in three adults and one in ten children experienced ongoing sequelae. In adults, females and persons with pre-existing hypertension, and in children, persons with neurological comorbidities or allergic respiratory diseases are at higher risk of PCC. © 2022. The Author(s).
|
650 |
0 |
4 |
|a Adults
|
650 |
0 |
4 |
|a Children
|
650 |
0 |
4 |
|a COVID-19
|
650 |
0 |
4 |
|a COVID-19 sequelae
|
650 |
0 |
4 |
|a Long COVID
|
650 |
0 |
4 |
|a PASC
|
650 |
0 |
4 |
|a Post-acute sequelae of SARS-CoV-2 infection
|
650 |
0 |
4 |
|a Post-COVID-19 condition
|
650 |
0 |
4 |
|a Prevalence
|
650 |
0 |
4 |
|a Risk factor
|
700 |
1 |
|
|a Abdeeva, E.
|e author
|
700 |
1 |
|
|a Andreeva, M.
|e author
|
700 |
1 |
|
|a Apfelbacher, C.
|e author
|
700 |
1 |
|
|a Avdeev, S.
|e author
|
700 |
1 |
|
|a Baimukhambetova, D.
|e author
|
700 |
1 |
|
|a Bairashevskaia, A.
|e author
|
700 |
1 |
|
|a Bobkova, P.
|e author
|
700 |
1 |
|
|a Bondarenko, E.
|e author
|
700 |
1 |
|
|a Borzakova, S.
|e author
|
700 |
1 |
|
|a Brackel, C.L.H.
|e author
|
700 |
1 |
|
|a Bugaeva, P.
|e author
|
700 |
1 |
|
|a Bulanov, N.
|e author
|
700 |
1 |
|
|a Buonsenso, D.
|e author
|
700 |
1 |
|
|a Butnaru, D.
|e author
|
700 |
1 |
|
|a Carson, G.
|e author
|
700 |
1 |
|
|a Comberiati, P.
|e author
|
700 |
1 |
|
|a Deunezhewa, S.
|e author
|
700 |
1 |
|
|a DunnGalvin, A.
|e author
|
700 |
1 |
|
|a El-Taravi, Y.
|e author
|
700 |
1 |
|
|a Filippova, Y.
|e author
|
700 |
1 |
|
|a Fomin, V.
|e author
|
700 |
1 |
|
|a Gamirova, A.
|e author
|
700 |
1 |
|
|a Genuneit, J.
|e author
|
700 |
1 |
|
|a Glybochko, P.
|e author
|
700 |
1 |
|
|a Greenhawt, M.
|e author
|
700 |
1 |
|
|a Guekht, A.
|e author
|
700 |
1 |
|
|a Kapustina, V.
|e author
|
700 |
1 |
|
|a Korsunskiy, A.A.
|e author
|
700 |
1 |
|
|a Mazankova, L.
|e author
|
700 |
1 |
|
|a Miroshina, A.
|e author
|
700 |
1 |
|
|a Munblit, D.
|e author
|
700 |
1 |
|
|a Needham, D.M.
|e author
|
700 |
1 |
|
|a Nekliudov, N.
|e author
|
700 |
1 |
|
|a Olliaro, P.
|e author
|
700 |
1 |
|
|a Osmanov, I.M.
|e author
|
700 |
1 |
|
|a Pazukhina, E.
|e author
|
700 |
1 |
|
|a Peroni, D.G.
|e author
|
700 |
1 |
|
|a Petrova, P.
|e author
|
700 |
1 |
|
|a Pikuza, M.
|e author
|
700 |
1 |
|
|a Reyes, L.F.
|e author
|
700 |
1 |
|
|a Rumyantsev, M.
|e author
|
700 |
1 |
|
|a Samitova, E.
|e author
|
700 |
1 |
|
|a Scott, J.T.
|e author
|
700 |
1 |
|
|a Sechenov StopCOVID Research Team
|e author
|
700 |
1 |
|
|a Semple, M.G.
|e author
|
700 |
1 |
|
|a Shikhaleva, A.
|e author
|
700 |
1 |
|
|a Sigfrid, L.
|e author
|
700 |
1 |
|
|a Spiridonova, E.
|e author
|
700 |
1 |
|
|a Svistunov, A.A.
|e author
|
700 |
1 |
|
|a Timashev, P.
|e author
|
700 |
1 |
|
|a Warner, J.O.
|e author
|
773 |
|
|
|t BMC medicine
|